Abstract
Background: Non-invasive methods to diagnose invasive fungal infections are needed to improve the poor outcome of these infections. We conducted this study to evaluate the diagnostic values of quantitative real time polymerase chain reaction and galactomannan in hematological malignancy patients. Results: Eighty-two consecutive patients with cancer were identified and prospectively followed for three months. Molecular testing using a quantitative polymerase chain reaction assay amplifying two primers 5.8S and 18S rRNA fungal genes and galactomannan was performed on 1540 blood samples and correlated with clinical data. Amplification of the 5.8S rRNA fungal gene had significantly higher sensitivity than amplification of the 18S rRNA gene for samples from either source (for blood samples: 90% vs 50%, p=0.007; for serum samples: 64% vs 5%, p<0.001). Conclusions: Galactomannan when used alone had a sensitivity of 38% and a specificity of 100%. The sensitivity of the combination assay of quantitative polymerase chain reaction plus galactomannan was significantly higher than that of GM test alone (71% vs 38%, p=0.03). Detection of the 5.8S rRNA fungal gene had significantly higher sensitivity than the 18S rRNA gene for samples from either source blood or serum. The combination of quantitative polymerase chain reaction plus galactomannan assay improved the diagnostic value of invasive fungal infections.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.